Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1988 Sep;26(9):1881–1883. doi: 10.1128/jcm.26.9.1881-1883.1988

Evaluation of immunoglobulin G preparations for anti-cytomegalovirus antibodies with reference to neutralizing antibody in the presence of complement.

Y Eizuru 1, I Ueno 1, Y Minamishima 1
PMCID: PMC266739  PMID: 2846652

Abstract

Eighteen commercially available immunoglobulin G (IgG) preparations were evaluated by various methods for anti-cytomegalovirus (CMV) antibodies. The modifications of immunoglobulin G molecules, such as sulfonation, alkylation, and enzyme treatments, resulted in profound reductions in anti-CMV antibody titers. However, after reversion in vitro, sulfonated IgG preparations which have been shown to be reverted in vivo (Y. Masuho, K. Tomibe, K. Matsuzawa, T. Watanabe, S. Ishimoto, S. Tsunoda, and T. Noguchi, J. Biochem. 79:1377-1379, 1976) restored the anti-CMV antibody titers to levels comparable with those of nonsulfonated IgG preparations. There is no good correlation among the titers tested by different methods. As a method which reflects the biological activities in vivo, the neutralization test in the presence of complement is suitable for the evaluation of IgG preparations.

Full text

PDF
1881

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araullo-Cruz T. P., Ho M., Armstrong J. A. Protective effect of early serum from mice after cytomegalovirus infection. Infect Immun. 1978 Sep;21(3):840–842. doi: 10.1128/iai.21.3.840-842.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Condie R. M., Hall B. L., Howard R. J., Fryd D., Simmons R. L., Najarian J. S. Treatment of life-threatening infections in renal transplant recipients with high-dose intravenous human IgG. Transplant Proc. 1979 Mar;11(1):66–68. [PubMed] [Google Scholar]
  3. Condie R. M., O'Reilly R. J. Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin. Dev Biol Stand. 1982;52:501–513. [PubMed] [Google Scholar]
  4. Dijkmans B. A., Versteeg J., Kauffmann R. H., van den Broek P. J., Eernisse J. G., van Zanten J. J., Bakker W., Kalff M. W., van Hooff J. P. Treatment of cytomegalovirus pneumonitis with hyperimmune plasma. Lancet. 1979 Apr 14;1(8120):820–821. doi: 10.1016/s0140-6736(79)91335-7. [DOI] [PubMed] [Google Scholar]
  5. Furukawa T., Hornberger E., Sakuma S., Plotkin S. A. Demonstration of immunoglobulin G receptors induced by human cytomegalovirus. J Clin Microbiol. 1975 Oct;2(4):332–336. doi: 10.1128/jcm.2.4.332-336.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Keller R., Peitchel R., Goldman J. N., Goldman M. An IgG-Fc receptor induced in cytomegalovirus-infected human fibroblasts. J Immunol. 1976 Mar;116(3):772–777. [PubMed] [Google Scholar]
  7. Lewis R. B., Matzke D. S., Albrecht T. B., Pollard R. B. Assessment of the presence of cytomegalovirus-neutralizing antibody by a plaque-reduction assay. Rev Infect Dis. 1986 Jul-Aug;8 (Suppl 4):S434–S438. doi: 10.1093/clinids/8.supplement_4.s434. [DOI] [PubMed] [Google Scholar]
  8. Masuho Y., Tomibe K., Matsuzawa K., Watanabe T., Ishimoto S. Reconstruction of intact gamma-globulin from S-sulfonated gamma-globulin in vivo. J Biochem. 1976 Jun;79(6):1377–1379. doi: 10.1093/oxfordjournals.jbchem.a131192. [DOI] [PubMed] [Google Scholar]
  9. Masuho Y., Tomibe K., Watanabe T., Fukumoto Y. Development of an intravenous gamma-globulin with Fc activities. II. Reconversion of S-sulfonated human gamma-globulin into the original gamma-globulin. Vox Sang. 1977;32(5):290–295. doi: 10.1111/j.1423-0410.1977.tb00648.x. [DOI] [PubMed] [Google Scholar]
  10. Meyers J. D., Leszczynski J., Zaia J. A., Flournoy N., Newton B., Snydman D. R., Wright G. G., Levin M. J., Thomas E. D. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med. 1983 Apr;98(4):442–446. doi: 10.7326/0003-4819-98-4-442. [DOI] [PubMed] [Google Scholar]
  11. Rahman A. A., Teschner M., Sethi K. K., Brandis H. Appearance of IgG (Fc) receptor(s) on cultured human fibroblasts infected with human cytomegalovirus. J Immunol. 1976 Jul;117(1):253–258. [PubMed] [Google Scholar]
  12. Schmitz H., Essuman S. Comparison of the neutralizing and ELISA antibody titres to human cytomegalovirus (HCMV) in human sera and in gamma globulin preparations. J Med Virol. 1986 Oct;20(2):177–182. doi: 10.1002/jmv.1890200209. [DOI] [PubMed] [Google Scholar]
  13. Shanley J. D., Jordan M. C., Stevens J. G. Modification by adoptive humoral immunity of murine cytomegalovirus infection. J Infect Dis. 1981 Feb;143(2):231–237. doi: 10.1093/infdis/143.2.231. [DOI] [PubMed] [Google Scholar]
  14. Stalder H., Ehrensberger A. Microneutalization of cytomegalovirus. J Infect Dis. 1980 Jul;142(1):102–105. doi: 10.1093/infdis/142.1.102. [DOI] [PubMed] [Google Scholar]
  15. Winston D. J., Pollard R. B., Ho W. G., Gallagher J. G., Rasmussen L. E., Huang S. N., Lin C. H., Gossett T. G., Merigan T. C., Gale R. P. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med. 1982 Jul;97(1):11–18. doi: 10.7326/0003-4819-97-1-11. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES